Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib

cancertherapyadvisor.com - 02-19

0L6UFfI7

Patients with chronic-phase chronic myeloid leukemia (CP-CML) are more likely to switch from generic imatinib than brand-name imatinib, largely due to adverse events, according to a study of Canadian patients with CML. The study was recently published in Haematologica.1.